Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of GZR18 injection in adults with obesity or overweight
CTR20244647Phase 3Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bofanglutide in obesity, Overweight, sponsored by Gannex Pharma Co., Ltd.. Started Dec 2024; status: completed.
02
Drugs
bofanglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20244647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244647.